859 reports of this reaction
2.4% of all ZIPRASIDONE reports
#5 most reported adverse reaction
TYPE 2 DIABETES MELLITUS is the #5 most commonly reported adverse reaction for ZIPRASIDONE, manufactured by ROERIG. There are 859 FDA adverse event reports linking ZIPRASIDONE to TYPE 2 DIABETES MELLITUS. This represents approximately 2.4% of all 36,171 adverse event reports for this drug.
Patients taking ZIPRASIDONE who experience type 2 diabetes mellitus should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
TYPE 2 DIABETES MELLITUS is a less commonly reported adverse event for ZIPRASIDONE, but still significant enough to appear in the safety profile.
In addition to type 2 diabetes mellitus, the following adverse reactions have been reported for ZIPRASIDONE:
The following drugs have also been linked to type 2 diabetes mellitus in FDA adverse event reports:
TYPE 2 DIABETES MELLITUS has been reported as an adverse event in 859 FDA reports for ZIPRASIDONE. This does not prove causation, but indicates an association observed in post-market surveillance data.
TYPE 2 DIABETES MELLITUS accounts for approximately 2.4% of all adverse event reports for ZIPRASIDONE, making it a notable side effect.
If you experience type 2 diabetes mellitus while taking ZIPRASIDONE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.